Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by wildbird1on Sep 04, 2019 1:16pm
75 Views
Post# 30094877

RE:RE:RE:More insider activity

RE:RE:RE:More insider activityOn Aug 31, and Sept 03, 2019, insiders bought for approximately $1.5 million in warrants and options.

At this very critical period in time, doesn't hurt to have more money in the Bank.


wildbird1 wrote: If you check the insider activity provided by Nailbiter1 on CEO.CA (SZLS), you will notice that on 2019,08,31 a total of 1,787,752 warrants were exercised by Rorry Riggs (director) at a price of 0.18$ each.

The big question is why would R.Riggs pay 0.18$ for each warrants when the current SP was  less than half the price (0.085$).

If you read my last post (Cessation Of  Billing) you will notice that the Billing process was stopped on march 31, 2019 and will resume in Q3 or Q4, 2019.
This could mean a noticable jump in revenue in Q3 or Q4.

My guess is that Rorry Riggs did pay 0.18$ for each warrants because he expect the SP(and revenue) to be much higher in Q3 or Q4, 2019.


KPOIndustries wrote: This is very interesting. One could assume that execs of StageZero are loading up on their position prior to an expected upswing....
Why else would one invest so much into the company at that level? Haters can hate, but the reality is, management clearly believes in the company and there is no reason for retailer investors to not believe.

Nailbiter1 wrote:
Latest one to take advantage of stock options.........................Filed 2019-09-03 19:13
Tx date 2019-08-23 $SZLS StageZero Life Sciences Ltd.
MacRae, Garth A. C.
4 - Director of Issuer
Options
50 - Grant of options $93,896
+938,960 vol
$0.10 each
2,077,920

 




Bullboard Posts